St. Jude FlexAbility Ablation Trial For Ventricular Tachycardia
This article was originally published in The Gray Sheet
Executive Summary
The company will be recruiting around 1,450 patients at 50 U.S. sites during the next four to five years to prove its ablation therapy is a valuable addition to ICDs or CRT-Ds to reduce recurrent ventricular tachycardia.
You may also be interested in...
St. Jude Medical Expands Presence In Electrophysiology Market With New Advanced Ablation Catheter
St. Jude Medical expands its presence in the electrophysiology market after gaining European regulatory approval of FlexAbility, the company’s next-generation flexible ablation catheter, and expects to receive US FDA 510(k) clearance for the device by year-end.
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.